在小儿B细胞前体急性淋巴细胞白血病中,CD9塑造了葡萄糖皮质激素敏感性
Chi Zhang1, Kathy Yuen Yee Chan1, Wing Hei Ng1
1Department of Paediatrics, The Chinese University of Hong Kong, Shatin.
Haematologica
|April 4, 2024
概括
在儿童B细胞前体急性淋巴细胞白血病 (BCP-ALL) 中,CD9细胞驱动对葡萄糖皮质体 (GC) 的耐药性. 向CD9可能会克服这种耐药性,改善BCP-ALL儿童的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 儿科血液学 儿科血液学
背景情况:
- 葡萄糖皮质醇 (GC) 对于诱导儿科B细胞前体急性淋巴细胞白血病 (BCP-ALL) 缓解至关重要.
- 在BCP-ALL治疗中,GC耐药性是一个主要的挑战,需要对潜在机制进行研究.
- 识别影响GC敏感性的因素可以导致新的治疗策略.
研究的目的:
- 为了研究CD9表达在BCP-ALL中调解葡萄糖皮质体耐药性的作用.
- 探索BCP-ALL细胞中CD9和GC敏感性之间的功能联系.
- 评估潜在的治疗策略,针对CD9介导的GC耐药性.
主要方法:
- 对BCP-ALL细胞进行CD9表达的表型分析.
- 在体外和体外功能增益和丧失实验中,评估CD9对GC敏感性的影响.
- 对GC受体 (NR3C1) 相互作用和下游基因表达的分析.
- 与MEK抑制剂特拉美丁尼和GC在CD9-表达和非表达BCP-ALL细胞中的协同效应研究.
主要成果:
- CD9-BCP-ALL细胞表现出对普得尼松和甲的优先耐药性.
- CD9表型与预尼松前期反应不佳有关,特别是在具有不良预后特征的患者中.
- CD9表达直接影响了GC易感性,CD9低细胞显示反向抵抗,CD9高细胞获得抵抗.
- 在不影响NR3C1表达或转位的情况下,CD9增强了GC响应基因诱导.
- 特拉美替尼布与GC对CD9-淋巴细胞的协同作用增强,逆转药物耐药性.
结论:
- CD9在BCP-ALL中调节GC敏感性方面发挥了以前未知的作用.
- CD9表型是儿科BCP-ALL中GC耐药性的重要决定因素.
- 向CD9或使用涉及MEK抑制剂的组合疗法可能为治疗GC耐药BCP-ALL.提供新的途径.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
10:21Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
9.9K
相关概念视频
Immunodeficiency Diseases
937
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
937
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
